Abstract
Methods -Model for CalculaXon of UXlity Cost
• Clinical u-lity is defined as the usefulness of a test for clinical prac-ce and is dis-nct from clinical validity, which is how well the test can determine the presence, absence, or risk of a specific disease. 1 • The model assumes that the clinical u-lity of a molecular profiling approach must demonstrate whether they lead to a reconsidera-on of the treatment plan and whether this improves the clinical outcome in profiled pa-ents.
• U-lity cost was defined as the list price divided by the frac-on of pa-ents treated based upon the profiling results and the clinical benefit in treated pa-ents.
• The u-lity cost is a reflec-on of the clinical u-lity and indicates the cost needed to treat one pa-ent with clinical benefit. • Sta-s-cal analysis (unpaired t-tests) was performed using GraphPad TM .
• List prices for the respec-ve services were based on telephone enquiry or accessed online. 2,3
Results -Graphical RepresentaXon of Clinical UXlity in 100 profiled paXents
• In a hypothe-cal popula-on of 100 pa-ents, significantly more pa-ents are treated using CMI compared to FMI (p<0.0001, 95% CI 0.47 to 0.69) or PCDx (p<0.0001; 95% CI 0.39 to 0.63).
• There was no significant difference between pa-ents treated when FMI and PCDx were used as the profiling approach (p=0.2380; 955 CI -0.19 to 0.05).
• Significantly more pa-ents of the overall cohort profiled experience clinical benefit when using CMI compared to FMI (p<0.0001; 95% CI 0.17 to 0.39) or PCDx (p<0.0001; 95% CI 0.13 to 0.35).
• There was no significant difference between levels of profiled pa-ents with clinical benefit when FMI and PCDx were used as the profiling approach (p=0.2995; 95% CI -0.12 to 0.04).
Study Highlights -UXlity Cost Differs Between Profiling Approaches
• The U-lity Cost (or the cost of profiling per pa-ent tested with clinical benefit) using CMI at $19,118 and is less than a quarter of the equivalent cost of $96,667 using FMI's NGS only approach and half that of PCDX ($43,636).
Results
• Seventy-seven percent (411 of 534) of pa-ents profiled with CMI were treated in line with the report. Of these, 88% (365 of 411) were evaluable. Fihy percent of evaluable pa-ents (184 of 365) had clinical benefit. The overall clinical u-lity was 34% (184 of 534 profiled pa-ents).
• Nineteen percent (499 of 2,675) of pa-ents profiled using FMI were treated in line with the profiling findings. Of these, 98% (488 of 499) were evaluable. Thirty-four percent of evaluable pa-ents (166 of 488) had clinical benefit. This represents an overall clinical u-lity of 6% (166 of 2,675 profiled pa-ents).
• Twenty-six percent (44 of 168) of pa-ents profiled using PCDx were treated in line with the report, of whom all were considered evaluable. Forty-three percent of treated pa-ents had clinical benefit, represen-ng an overall clinical u-lity of 11% (19 of 168 profiled pa-ents).
Conclusions
• Significantly more pa-ents are treated using CMI's mul-plaZorm profiling approach, which provides the most comprehensive informa-on (on which chemotherapies, hormone therapies and immunotherapies to use as well as which targeted therapies are suitable) compared to those focused on targeted therapies alone.
• The impact on treatment choice is directly dependent on the panel of biomarkers tested, the frequency of those biomarkers in the popula-on and the level of evidence presented to the oncologist in support of a change in treatment decision.
• The individual pa-ent's likelihood of clinical benefit within the whole profiled pa-ent group is the most cri-cal measure for a pa-ent and their oncologist when seing expecta-ons of what a molecular profile can offer.
• The cost of profiling does not include any considera-on for the recommended therapies, which would further extend the gap in cost given the high price of targeted therapies compared to conven-onal cytotoxic agents.
• The value of profiling should not be considered as a reflec-on of the unit cost but rather the amount that needs to be invested to bring clinical benefit to a single pa-ent.
• Precision medicine using a sequencing-only approach brings such low clinical u-lity that the costs seem unsustainable outside of a research seing.
Background
• Molecular tumor profiling for pa-ents with advanced or recurrent solid tumors is increasingly adopted as standard of care in oncology, as it has been demonstrated that improved clinical outcomes can result from selec-on of the op-mal therapy for individual pa-ents.
• Ini-al large scale arempts to profile pa-ents in the hope of direc-ng them to molecularly matched clinical trials have highlighted that only a small propor-on of pa-ents have ac-onable altera-ons which are suitable for enrollment into a trial.
• For oncologists who are ac-vely integra-ng tumor profiling into their pa-ent's care today, it can be challenging to understand the differences in clinical u-lity and benefit between numerous available molecular profiling services. The ohenconsiderable costs at the pa-ent's expense require jus-fica-on.
• The aim of this study is to to compare and contrast the clinical u-lity of 3 commercial approaches, to show that not all approaches to precision medicine are the same in terms of quality and cost-effec-veness.
Methods
• Three commercially available services were included in this analysis -Caris Molecular Intelligence ® from Caris Life Sciences, Founda-onOne ® from Roche/ Founda-on medicine, PCDx ™ from Paradigm. • Key differences between molecular profiling services lie in the range and scope of plaZorms used to assess biomarkers. 
